Botanical species · safety record

Aframomum melegueta

The EFSA Compendium of Botanicals holds 19 constituent measurements and 6 adverse-effect records for Aframomum melegueta. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Aframomum melegueta K.Schum.

19Constituent measurements
6Safety records
11Cited sources
82Licensed products (Canada)

Also recorded as

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 82 licensed products naming Aframomum melegueta as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

  • Dry

Source material stated

  • Fruit
  • Graine
  • New material
  • Seed
  • Seed(s)
  • Whole plant

What the records describe

Constituents measured

  • 1,8-cineole3
  • 6-gingerol3
  • Alpha-phellandrene2
  • Shogaols2
  • Angustifoline1
  • Arctigenin1
  • Carboline alkaloids1
  • Indicine1
  • Lupanine1
  • Myrcene1

Plant parts

  • Seed14
  • Live plants5
  • Fruit unspecified2
  • Leaves1
  • Roots and other underground parts1

Preparations

  • Solvent extraction15
  • Essential oil6

Effect types

  • Digestive2
  • Hepatotoxicity1
  • Musclo-skeletal1
  • Other toxicities1
  • Reproductive1

Target tissues

  • Digestive2
  • Liver1
  • Muscle, skeletal1
  • Vagina1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
1,8-cineoleSeedEssential oil——Resolve DOI
1,8-cineoleLive plantsEssential oil≥ 47 PercentGC-MSResolve DOI
1,8-cineoleLive plantsEssential oil≤ 86 PercentGC-MSResolve DOI
6-gingerolSeedSolvent extraction—High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
6-gingerolSeedSolvent extraction15.2 PercentHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
6-gingerolFruit unspecifiedSolvent extraction—Nuclear Magnetic Resonance (NMR)Resolve DOI
Alpha-phellandreneLive plantsEssential oil≥ 0.5 PercentGC-MSResolve DOI
Alpha-phellandreneLive plantsEssential oil≤ 1.5 PercentGC-MSResolve DOI
AngustifolineSeedSolvent extraction—GC-MSResolve DOI
IndicineSeedSolvent extraction—GC-MSResolve DOI
LupanineSeedSolvent extraction—GC-MSResolve DOI
MyrceneSeedEssential oil——Resolve DOI
MyristicinSeedSolvent extraction—GC-MSResolve DOI
SafroleSeedSolvent extraction—GC-MSResolve DOI
SenkirkineSeedSolvent extraction—GC-MSResolve DOI
ShogaolsSeedSolvent extraction1.7 PercentHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
ShogaolsFruit unspecifiedSolvent extraction—Nuclear Magnetic Resonance (NMR)Resolve DOI
ArctigeninRoots and other underground partsSolvent extraction4.5 MilligramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)No resolvable identifier
Carboline alkaloidsLeavesSolvent extraction—Nuclear Magnetic Resonance (NMR)No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
DigestiveDigestive———In vitroResolve DOI
DigestiveDigestive———In vitroResolve DOI
HepatotoxicityLiverSeedSolvent extractionRat (as animal)Short-term toxicityResolve DOI
Musclo-skeletalMuscle, skeletalSeedSolvent extractionHuman (as organism)Short-term toxicityResolve DOI
Other toxicities—Seed—Human (as organism)Acute toxicityResolve DOI
ReproductiveVaginaLive plants—Rat (as animal)Short-term toxicityNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Igwe, SA., Emeruwa, IC., Modie, JA. Ocular toxicity of Afromomum melegueta (alligator pepper) on healthy Igbos of Nigeria . Journal of ethnopharmacology, 1999, vol. 65, no. 3, p. 203-206. DOI
  2. Ilic, Nebojsa., Schmidt, Barbara M., Poulev, Alexander., Raskin, Ilya. Toxicological evaluation of Grains of Paradise (Aframomum melegueta) Roscoe K. Schum. . Journal of ethnopharmacology, 2010, vol. 127, no. 2, p. 352-356. DOI
  3. Inegbenebor, U., Ebomoyi, M I., Onyia, K A., Amadi, K., Aigbiremolen, A E. Effect of alligator pepper (Zingiberaceae aframomum melegueta) on first trimester pregnancy in Sprague Dawley rats. . Nigerian journal of physiological sciences : official publication of the physiological society of nigeria, 2009, vol. 24, no. 2, p. 161-4.
  4. Sugita, Jun., Yoneshiro, Takeshi., Hatano, Takuya., Aita, Sayuri., Ikemoto, Takeshi., Uchiwa, Hideyo., Iwanaga, Toshihiko., Kameya, Toshimitsu., Kawai, Yuko., Saito, Masayuki. Grains of paradise (Aframomum melegueta) extract activates brown adipose tissue and increases whole-body energy expenditure in men . British journal of nutrition, 2013, vol. 110, no. 4, p. 733-738. DOI
  5. Ameh, Sunday J., Ibekwe, Nneka N., Ebeshi, Benjamin U. Essential Oils in Ginger, Hops, Cloves, and Pepper Flavored Beverages-A Review . Journal of dietary supplements, 2015, vol. 12, no. 3, p. 241-260. DOI
  6. Adefegha, Stephen A., Oboh, Ganiyu., Okeke, Bathlomew M., Oyeleye, Sunday I. Comparative Effects of Alkaloid Extracts from Aframomum melegueta (Alligator Pepper) and Aframomum danielli (Bastered Melegueta) on Enzymes Relevant to Erectile Dysfunction . Journal of dietary supplements, 2017, vol. 14, no. 5, p. 542-552. DOI
  7. Martin, M. A. Couppe de K., Joseph, H., Bercion, S., Menut, C. Chemical composition of essential oils from aerial parts of Aframomum exscapum (Sims) Hepper collected in Guadeloupe, French West Indies . Flavour and fragrance journal, 2006, vol. 21, no. 6, p. 902-905. DOI
  8. Fernandez, X., Pintaric, C., Lizzani-Cuvelier, L., Loiseau, AM., Morello, A., Pellerin, P. Chemical composition of absolute and supercritical carbon dioxide extract of Aframomum melegueta . Flavour and fragrance journal, 2006, vol. 21, no. 1, p. 162-165. DOI
  9. Dibwe, Dya Fita., Awale, Suresh., Morita, Hiroyuki., Tezuka, Yasuhiro. Anti-austeritic Constituents of the Congolese Medicinal Plant Aframomum melegueta . Natural product communications, 2015, vol. 10, no. 6, p. 997-999.
  10. Mohammeda, Aminu., Gbonjubola, Victoria Awolola., Koorbanally, Neil Anthony., Islam, Shahidul. Inhibition of key enzymes linked to type 2 diabetes by compounds isolated from Aframomum melegueta fruit . Pharmaceutical biology, 2017, vol. 55, no. 1, p. 1010-1016. DOI
  11. Okwu, Donatus Ebere., Njoku, Eunice Ego. Monoterpene indole alkaloid from Aframomum melegueta.. International journal of pharmtech research, 2010, vol. 2, no. 1, p. 910-913.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue